Therapy Areas: Respiratory
AstraZeneca reveals positive overall survival results from Imfinzi's Phase III CASPIAN trial
1 July 2019 -

United Kingdom-based AstraZeneca has revealed positive overall survival (os) results from the Phase III CASPIAN trial with Imfinzi in first line extensive-stage small cell lung cancer (SCLC), it was reported on Friday.

An Independent Data Monitoring Committee conducted a planned interim analysis that revealed that the trial has met its primary endpoint by indicating a statistically-significant and clinically-meaningful improvement in overall survival in patients treated with Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy options compared to chemotherapy alone.

CASPIAN is a randomised, open-label, multi-centre, global, Phase III trial of Imfinzi plus platinum-based chemotherapy options or the combination of Imfinzi, tremelimumab and chemotherapy, compared with chemotherapy alone as a first-line treatment for patients with extensive-stage SCLC. The trial will continue to the final analysis of overall survival for the combination of dual immune checkpoint blockade with chemotherapy. This combination includes tremelimumab, an anti-CTLA4 antibody and potential new medicine, with Imfinzi, an anti-PDL1 antibody, and chemotherapy.

The company is to submit these results for presentation at a forthcoming medical meeting.

Login
Username:

Password: